Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.
Authors
Christina X. Chamberlain
Servier Pharmaceuticals LLC, Boston, MA
Christina X. Chamberlain , Zhaowei Hua , Camelia Gliser , Shuchi S. Pandya , Andrew X. Zhu , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT02989857
DOI
10.1200/JCO.2022.40.4_suppl.388
Abstract #
388
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Targeted therapies in cholangiocarcinoma: Assessment of US oncologist practice patterns.
First Author: Kinjal Parikh
Poster
2020 Gastrointestinal Cancers Symposium
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.
First Author: Bin Fan
Poster
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: Ghassan K. Abou-Alfa
Poster
2017 ASCO Annual Meeting
Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
First Author: Maeve Aine Lowery